Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction

Dourado, Paulo Magno Martins; Tsutsui, Jeane Mike; Landim, Maurício Batista Paes; Filho, A Casella; Galvão, Tatiana; Aiello, Vera Demarchi; Mathias, Wilson; Luz, Protásio Lemos da; Chagas, A. C. P.

doi:10.1590/s0100-879x2011007500034

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Group C was divided into 7 subgroups of 12 rats each and were treated orally with different doses of rosuvastatin (1,2,5,10 &20mg/kg) (Dourado et al, 2011 andHabibi et al, 2007), cilostazol (18mg/kg) cilostazol was chosen corresponding to the human therapeutic doses and was calculated according to the method given by Paget and Barnes. (1964), and combination of rosuvastatin 1mg/kg and cilostazol 18mg/kg once daily for 16 days.…”

Section: C-mentioning

confidence: 99%

Effects of Rosuvastatin in Experimentally-Induced Cardiac Ischemia and on Aortic Vascular Reactivity.

Hamouda

2017

Al-Azhar Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Myocardial infarction (MI) continues to be a major public health problem in the world. The present study aimed to elucidate the protective effect of different doses of rosuvastatin and cilostazol, as well as their combination on isoprenaline-induced MI in rats as well as their effects on isolated aorta. Methods: I-Adult rats received different doses of rosuvastatin (1,2,5,10, & 20mg/kg), cilostazol (18mg/kg) and combination of rosuvastatin 1mg/kg and cilostazol 18mg/kg by oral gavage daily for 16 days, then rats were subcutaneously injected with two doses 24-h apart of 150mg/kg isoprenaline in the last two days. ECG pattern was monitored, myocardial injury markers (CK-MB and LDH) and inflammatory biomarker (CRP) were measured in serum. MDA, catalase and SOD were quantified in cardiac homogenates and heart tissue damage was examined by histopathology. II-Effects of rosuvastatin (0.2 µg/ml-6.4 µg/ml), cilostazol (7.5 µg/ml-480 µg/ml) and combination cilostazol (30 µg/ml) and rosuvastatin (0.2 µg/ml-6.4 µg/ml) on NE-induced contraction in rabbit aortic strip were recorded. Each dose of either rosuvastatin or cilostazol were incubated for 10 min and 15min respectively then NE (0.5 µg/ml) was added and the contraction was recorded for one and half min. Results: I-Pretreatment with different doses of rosuvastatin (1,2,5 & 10), cilostazol 18mg/kg and the combination markedly ameliorated ISO-induced alterations in ECG, cardiac markers, inflammatory marker, oxidative markers and heart architecture. However, protection disappeared at higher dose of rosuvastatin 20mg/kg. II-Addition of either rosuvastatin (0.2-6.4 µg/ml), cilostazol (7.5-480µg/ml) or combination rosuvastatin (0.2-6.4 µg/ml) and cilostazol 30µg/ml produced a significant decrease in the height of NE-induced contraction in a dose dependent manner. Conclusion: I-This study provides evidence that rosuvastatin, cilostazol and their combination possess cardioprotective effect on isoprenaline-induced myocardial infarction. II-The drugs had vasorelaxant effect on aorta. Mechanism of drug action are discussed.

show abstract

Section: C-mentioning

confidence: 99%

Effects of Rosuvastatin in Experimentally-Induced Cardiac Ischemia and on Aortic Vascular Reactivity.

Hamouda

2017

Al-Azhar Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction

Cited by 1 publication

References 28 publications

Effects of Rosuvastatin in Experimentally-Induced Cardiac Ischemia and on Aortic Vascular Reactivity.

Effects of Rosuvastatin in Experimentally-Induced Cardiac Ischemia and on Aortic Vascular Reactivity.

Contact Info

Product

Resources

About